Abstract 4976: The impact of obesity on survival in epithelial gynecological tumors

Abstract Background: The impact of obesity on the survival of patients with epithelial gynecological tumors is not yet clear. We aim to elucidate the impact of body mass index (BMI) on epithelial gynecological tumors in a large tertiary center at Saudi Arabia. Methods: We retrospectively reviewed the medical files of all patients with pathologically confirmed epithelial gynecological tumors at our center. Then, we assessed the difference in overall survival (OS) according to primary tumor location, BMI, stage at presentation, and performance status (PS) at presentation using log-rank tests. Results: 400 patients were included in the analysis. The mean age at diagnosis was 56. 1±13 years. 242 (60. 5%) patients were diagnosed with uterine carcinomas, 137 (34. 3%) with ovarian carcinomas, and 21 (5. 3%) with cervical carcinomas. 278 (69. 5%) patients were obese at presentation, 74 (18. 5%) were overweight, 43 (10. 8%) were within normal range, and 7 (1. 8%) were underweight. The PS at presentation was 0, 1, 2, 3, and 4 in 351 (87. 8%), 17 (4. 3%), 10 (2. 5%), 16 (4%), and 6 (1. 5%) patients, respectively. Cervical cancer was associated with long OS, while ovarian cancers demonstrated poor prognosis (p=0. 0159). There was no difference in OS between different BMI groups (p=0. 072). Patients with stage 4 cancers had significantly shorter OS (p0. 0001). Patients with PS 4 at presentation was associated with the worst prognosis (p0. 0001). Interpretation: Shorter OS was associated with ovarian carcinomas, advanced staging, and poor PS at presentation. BMI classification had no impact on OS. Further studies are needed to confirm our findings. Citation Format: Ahmed Badran, Mahmoud Elshenawy, Waleed Fallatah, Abdullaah K. Hinkston, Saad S. Ali, Mohammed Ali Omar, Abdulaziz M. Alaklabi, Hytham M. Abdalla, Tarek Z. Arabi, Belal N. Sabbah, Hamed Alhusaini. The impact of obesity on survival in epithelial gynecological tumors abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts) ; 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84 (6Suppl): Abstract nr 4976.